HPV Vaccination: What New Research Means for Your Family's Health

This informal CPD article ‘HPV Vaccination: What New Research Means for Your Family's Health’ was provided by Cima Care, who offer extensive training in vaccination and public health, advancing global health initiatives.

Understanding Recent Developments in Cancer Prevention

When it comes to preventing cancer, vaccines targeting the human papillomavirus (HPV) have been in use for nearly two decades. Research continues to provide insights into their effectiveness, safety, and optimal administration. This article reviews recent findings that may inform vaccination decisions.

The Cancer Connection

Cervical cancer affects over 340,000 families worldwide annually, with largely preventable deaths. (1, 2) The human papillomavirus (HPV) is responsible not only for cervical cancer but also for cancers of the throat, mouth, anus, penis, and other areas, affecting both women and men. (1)

Current vaccines can prevent approximately 90% of HPV-related cancers. (1, 3) Recent studies have provided data on protection that may be simpler to achieve than previously thought.

Single-Dose Research: New Clinical Evidence

For years, health authorities recommended two or three doses of the HPV vaccine. Research published in late 2023 has provided new data on the effectiveness of a single dose.

The Kenya Clinical Trial

A clinical trial in Kenya tracked young women who received a single dose of the HPV vaccine. Results published in December 2023 showed 97.5% protection against the cancer-causing HPV types. (4)

Three-year follow-up data indicated that protection had remained stable. (5)

Long-Term Protection Data

Studies examining whether single-dose protection persists have been conducted in multiple settings. A research study from Costa Rica, published in November 2024, followed participants for 16 years after a single dose. Antibody levels remained "stably robust" throughout the study period, with declines described by the researchers as modest. Based on antibody behaviour patterns, protection may last at least 20 years and possibly longer. (6)

A 12-year study from India followed participants after HPV vaccination and examined both infection rates and precancerous cellular changes detectable during cervical screening. The study found comparable protection whether participants received one, two, or three doses. This was the first study globally to demonstrate that a single HPV vaccine dose prevents precancerous changes, not just initial virus infection. (7)

Real-World Outcomes: Population-Level Data

Evidence from countries that introduced HPV vaccination over a decade ago has accumulated.

Cervical Cancer Incidence

A 2025 review found that girls vaccinated before age 16 were 80% less likely to develop cervical cancer compared to unvaccinated individuals. (8)

A study from Scotland in November 2025, found that HPV vaccine protection against cervical disease persisted for over 12 years. The population-based study showed that girls vaccinated at ages 12 or 13 experienced the greatest benefits. The study also found greater benefits in women from economically disadvantaged areas, suggesting vaccination may help reduce health inequalities. (9)

Population-Wide Effects

A 17-year study published in September 2025 documented outcomes as vaccination coverage increased in one US community from 0% to 82%. HPV infection rates decreased not only among vaccinated individuals but also among unvaccinated people. Infections from vaccine-targeted HPV types dropped by 98.4%. (10)

This represents herd immunity: when vaccination coverage reaches certain levels, virus transmission to unvaccinated individuals decreases. (11)

Male Vaccination: Expanding Coverage

HPV vaccination programmes initially focused on girls and young women. Research increasingly examines outcomes when programmes include males.

The Male Disease Burden

HPV causes approximately 16,000 cancers annually in men, including cancers of the throat, mouth, anus, and penis. Head and neck cancers caused by HPV are increasing in many countries. (12) A 2024 modelling study from Finland found that vaccinating both boys and girls achieves population-level HPV control in approximately 8 years, versus 20 years with girls-only programmes. (13). As of April 2024, 54 countries have adopted gender-neutral vaccination strategies. (14)

cpd-Cima-Care-population-level-HPV-control
Population level HPV control

Safety: Data from 270 Million Doses

The World Health Organization's Global Advisory Committee on Vaccine Safety has repeatedly reviewed HPV vaccines, analysing data from more than 270 million doses distributed worldwide. Their conclusion, reaffirmed from 2017 through 2025: HPV vaccines have an "excellent safety profile". (10, 16)

Documented Reactions

The most common reactions are mild and temporary (10, 12).

  • Pain at injection site: 80-90% of recipients (resolves within 48-72 hours)
  • Mild swelling: 20-30%
  • Low-grade fever: 10-15%

Serious reactions are rare. The only serious reaction with clear evidence of causation is anaphylaxis (severe allergic reaction), occurring in approximately 1-2 cases per million doses, comparable to other routine vaccines. (10)

Long-Term Health Studies

Research has specifically examined whether HPV vaccination increases risks of the following:

  • Autoimmune diseases: No increased risk found
  • Fertility problems: No increased risk found
  • Neurological disorders: No increased risk found (10)

A 2025 research review confirmed: "No evidence to support claims that HPV vaccination increases the risk of serious adverse events." (8)

Timing: Age and Effectiveness

Research has examined vaccine effectiveness across different age groups.

Age-Related Effectiveness

A 2023 analysis of 21 studies found vaccine effectiveness highest when given at ages 9-14 years, with protection rates of 74-93% in this age group. When vaccination occurred at ages 15-18, effectiveness ranged from 12% to 90%. (17, 18)

HPV vaccines provide protection before exposure to the virus, which typically occurs through sexual contact. (17) Vaccination during early adolescence, before most people become sexually active, has been associated with stronger protection.

Current Recommendations

The World Health Organization updated guidance in December 2022 (19, 20):

  • Ages 9-20: One or two doses (single dose accepted as effective alternative)
  • Ages 21+: Two doses
  • Immunocompromised individuals: Three doses, regardless of age (21-24)

The acceptance of single-dose schedules for adolescents may allow protection of more people with existing vaccine supplies. (20)

Global Implementation

The World Health Organization has set 2030 targets to eliminate cervical cancer as a public health problem, termed the 90-70-90 strategy:

  • 90% of girls fully vaccinated by age 15
  • 70% of women screened with high-performance tests by ages 35 and 45
  • 90% of women with cervical disease receiving appropriate treatment

As of December 2025, 159 countries (82%) have introduced HPV vaccines into national immunisation programmes, representing progress from 4 countries in 2006. (25) Global coverage rates show approximately 62% of girls receive a first dose, and 48% complete the full course. (26)

Frequently Asked Questions

Q: If vaccination was missed at the recommended age, can it still be given?

A: Catch-up vaccination for people aged 15-26 who missed earlier doses may still provide benefit, though protection is highest when given before sexual debut. (21-24)

Q: Do vaccinated individuals still need cervical cancer screening?

A: Yes. While HPV vaccines prevent approximately 90% of cervical cancers, they do not prevent all types. Screening remains important complementary protection. (1)

Q: Can the vaccine cause HPV infection?

A: No. HPV vaccines do not contain live virus and cannot cause HPV infection. (12)

Q: Why vaccinate males if they do not develop cervical cancer?

A: HPV causes approximately 16,000 cancers in men annually, including throat, mouth, anal, and penile cancers. Additionally, male vaccination contributes to achieving herd immunity more rapidly. (12, 13)

Summary

Research involving millions of people indicates HPV vaccination is effective at preventing HPV-related cancers. Recent studies showing single doses provide durable protection may make this intervention more accessible, particularly for communities with limited healthcare access. For those making vaccination decisions, the evidence demonstrates HPV vaccines are effective, have a favourable safety profile, and can prevent substantial numbers of cancers annually. 

We hope this article was helpful. For more information from Cima Care, please visit their CPD Member Directory page. Alternatively, you can go to the CPD Industry Hubs for more articles, courses and events relevant to your Continuing Professional Development requirements.

References:

  1. Ghosh A, Chatterjee S, Dawn A, Das A. HPV Vaccines – An Overview. Indian Journal of Dermatology [Internet]. 2025 Jun 30;70(4):188–200. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12306887/
  2. Miazga W, Tatara T, Mariusz Gujski, Pinkas J, Ostrowski J, Urszula Religioni. Global Guidelines and Trends in HPV Vaccination for Cervical Cancer Prevention. Medical Science Monitor [Internet]. 2025 Mar 6;31. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12039458/
  3. Kim J, Young June Choe, Park J, Cho J, Cheong C, Oh JK, et al. Comparative Effects of Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines in The Prevention of Genotype-Specific Infection: A Systematic Review and Network Meta-Analysis. Infection and chemotherapy [Internet]. 2024 Jan 1;56(1):37–7. Available from: https://doi.org/10.3947%2Fic.2023.0064
  4. Ben-Ari E. One HPV vaccine dose prevents cancer-causing infections - NCI [Internet]. www.cancer.gov. 2022. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2022/cervical-cancer-hpv-vaccine-one-dose-kenya
  5. Barnabas RV, Brown ER, Onono MA, Bukusi EA, Njoroge B, Winer RL, et al. Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results. Nature Medicine [Internet]. 2023 Dec 1;29(12):3224–32. Available from: https://www.nature.com/articles/s41591-023-02658-0
  6. Porras C, Romero B, Hernández BY, Herrero R, Rodríguez AC, Safaeian M, et al. HPV16/18 antibodies 16‑years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial. J Natl Cancer Inst Monogr. 2024;2024(67):329‑336
  7. Malvi SG, Esmy PO, Muwonge R, Joshi S, Poli URR, Lucas E, et al. A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccination. Journal of the National Cancer Institute Monographs [Internet]. 2024 Jan;2024(67):317–28. Available from: https://pubmed.ncbi.nlm.nih.gov/39529521/
  8. Parkinson M. New research confirms HPV vaccination prevents cervical cancer | Cochrane [Internet]. Cochrane.org. 2025. Available from: https://www.cochrane.org/about-us/news/new-research-confirms-hpv-vaccination-prevents-cervical-cancer
  9. Palmer TJ, Kavanagh K, Cuschieri K, Cameron RL, Graham C, Wilson A, et al. Sustained impact of bivalent HPV immunisation on CIN incidence over two rounds of cervical screening. International Journal of Cancer. 2025 Nov 3;158(5):1348–60.
  10. Welcome To Zscaler Directory Authentication [Internet]. Prnewswire.com. 2026 [cited 2026 Feb 12]. Available from: https://www.prnewswire.com/news-releases/study-shows-hpv-vaccine-protects-vaccinatedand-unvaccinatedwomen-302568507.html
  11. HHS. Vaccines Protect Your Community [Internet]. HHS.gov. 2021. Available from: https://www.hhs.gov/immunization/basics/work/protection/index.html
  12. Lipsky MS, Gunnell B, Nguyen J, Lee S, Wolfe G, Hung M. HPV Prevention in Men: A Narrative Review of Strategies, Risks, and Public Health Implications. American Journal of Men's Health. 2025 Nov;19(6).
  13. Naidoo D, Govender K, Mantell JE. Breaking barriers: why including boys and men is key to HPV prevention. BMC Medicine. 2024 Nov 8;22(1).
  14. Schuind AE, Balaji KA, Du A, Yuan Y, Dull P. Human papillomavirus prophylactic vaccines: update on new vaccine development and implications for single-dose policy. Journal of the National Cancer Institute Monographs [Internet]. 2024 Jan;2024(67):410–6. Available from: https://pubmed.ncbi.nlm.nih.gov/39529522/
  15. Allen F. Call for global gender-neutral HPV vaccination by 2030 [Internet]. The Microbiologist. 2024 [cited 2026 Feb 12]. Available from: https://www.the-microbiologist.com/news/call-for-global-gender-neutral-hpv-vaccination-by-2030/4093.article
  16. Boys, Men and HPV - GLOBAL ACTION ON MEN'S HEALTH [Internet]. GLOBAL ACTION ON MEN'S HEALTH - Improving the health of men and boys. 2024 [cited 2026 Feb 12]. Available from: https://gamh.org/boys-men-hpv/
  17. Ellingson MK, Sheikha H, Nyhan K, Oliveira CR, Niccolai LM. Human papillomavirus vaccine effectiveness by age at vaccination: A systematic review. Human vaccines & immunotherapeutics [Internet]. 2023;19(2):2239085. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399474/
  18. Mehran Rostami Varnousfaderani, Zahedeh Khoshnazar, Hamidreza Zeratie, Parisa Hosseini Koukamari. Optimizing HPV vaccine effectiveness: impact of vaccination age and dose schedule on immunogenicity and cervical cancer prevention. Frontiers in Public Health. 2025 May 7;13.
  19. World Health Organization. Human papillomavirus vaccines: WHO position paper, December 2022 [Internet]. www.who.int. 2022. Available from: https://www.who.int/publications/i/item/who-wer9750-645-672
  20. One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer - PAHO/WHO | Pan American Health Organization [Internet]. www.paho.org. Available from: https://www.paho.org/en/news/11-4-2022-one-dose-human-papillomavirus-hpv-vaccine-offers-solid-protection-against-cervical
  21. People with immunocompromising conditions are recommended to receive 3 doses of HPV vaccine [Internet]. The Australian Immunisation Handbook. 2023. Available from: https://immunisationhandbook.health.gov.au/recommendations/people-with-immunocompromising-conditions-are-recommended-to-receive-3-doses-of-hpv-vaccine
  22. Luo Q, Ni Q. Gender-neutral human papillomavirus vaccination: an equitable and cost-effective public health investment. Frontiers in Public Health. 2026 Jan 5;13.
  23. WHO. Human papillomavirus (HPV) [Internet]. www.who.int. 2022. Available from: https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/human-papillomavirus-vaccines-(HPV)
  24. WHO. WHO updates recommendations on HPV vaccination schedule [Internet]. www.who.int. 2022. Available from: https://www.who.int/news/item/20-12-2022-WHO-updates-recommendations-on-HPV-vaccination-schedule
  25. Julia, LaMontagne DS, Paul. Global status of HPV vaccination two decades in: effective, safe and preventing cancer. Expert Review of Vaccines. 2025 Dec 24;25(1):2609869–9.
  26. Han J, Zhang L, Chen Y, Zhang Y, Wang L, Cai R, et al. Global HPV vaccination programs and coverage rates: a systematic review. eClinicalMedicine [Internet]. 2025 Jun 9;84:103290. Available from: https://www.sciencedirect.com/science/article/pii/S2589537025002226